PREVAIL IV (Q5) Double-Blind Randomized Two-Phase Placebo Controlled Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus and Safety in Male Ebola Survivors with Evidence of Ebola Virus Persistence in Semen
|Effective start/end date||8/13/16 → 9/25/21|
- Leidos Biomedical Research, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.